Search | Clinical Trials Finder

Conditions: Eosinophilic Asthma
Interventions: Reslizumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 66
States / cities: Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more

Conditions: Osteogenesis Imperfecta
Interventions: Setrusumab, Placebo; Biological · Other
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 5 Years to 25 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 19 more

Conditions: Gout
Interventions: pegloticase; Biological
Lead sponsor: Savient Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 22
States / cities: San Francisco, California • Santa Maria, California • Whittier, California + 19 more

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Clazosentan, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 11
States / cities: Phoenix, Arizona • Englewood, Colorado • Boston, Massachusetts + 8 more

Conditions: Epilepsy, Healthy Volunteer
Interventions: SIF001, Placebo; Biological · Drug
Lead sponsor: Suninflam Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Tucson, Arizona • DeLand, Florida • Tamarac, Florida + 7 more

Conditions: Lumbar Osteoarthritis, Spondylosis, Lumbar Disc Disease, Spinal Stenosis
Interventions: Ketorolac, Acetaminophen, Placebo; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 75 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID, SARS-CoV2 Infection, Covid19
Interventions: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG), Placebo; Biological · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 16
States / cities: Tucson, Arizona • Mather, California • Palo Alto, California + 13 more

Conditions: Metastatic Breast Cancer
Interventions: Veliparib Placebo, Veliparib, Carboplatin, Paclitaxel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 56
States / cities: Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more

Conditions: Gout
Interventions: placebo, pegloticase; Other · Biological
Lead sponsor: Savient Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 45 more

Conditions: Metastatic Non Small Cell Lung Cancer
Interventions: Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more

Conditions: Bioavailability
Interventions: WCK 771 IV Infusion, Placebo IV Infusion; Drug · Other
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Eculizumab, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 19
States / cities: Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: Female only
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Post Menopausal Osteoporosis
Interventions: Denosumab, Zoledronic Acid, Placebo to Denosumab, Placebo to Zoledronic Acid; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years and older · Female only
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 9
States / cities: Santa Monica, California • Lakewood, Colorado • Longmont, Colorado + 6 more

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: PF-04950615 (RN316); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 9
States / cities: Culver City, California • Glendale, California • Miami, Florida + 4 more

Conditions: Colitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 21 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Healthy
Interventions: Oritavancin, Placebo (D5W); Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Patients With Acute Pancreatitis
Interventions: Dexamethasone acetate, Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 0 Hours to 72 Hours
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions: Alteplase, Unfractionated heparin, Placebo, Apixaban; Drug
Lead sponsor: Victor Tapson, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Belimumab 200 mg SC, Standard therapy; Biological · Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 839 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 82
States / cities: Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 68 more

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more

Conditions: Benign Prostatic Hyperplasia
Interventions: Tranexamic Acid (IV), Placebo; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 45 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Uterine Cramps, Postoperative Pain Management, Hysteroscopy
Interventions: Magnesium sulfate, Ketamine, Placebo; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Royal Oak, Michigan

Search by objective public record fields.

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Setrusumab vs Placebo for Osteogenesis Imperfecta

Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients

Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS

Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

Early Treatment With Dexamethasone in Mild Acute Pancreatitis

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation

Magnesium and Cramping